• OPEN AN ACCOUNT
Indian Indices
Nifty
24,718.60 -169.60
(-0.68%)
Sensex
81,118.60 -573.38
( -0.70%)
Bank Nifty
55,527.35 -555.20
( -0.99%)
Nifty IT
38,469.25 8.95
( 0.02%)
Global Indices
Nasdaq
42,214.73 -773.90
(-1.80%)
Dow Jones
5,997.34 -68.92
(-1.14%)
Hang Seng
37,801.43 -371.66
(-0.97%)
Nikkei 225
8,850.63 -34.29
(-0.39%)
Forex
USD-INR
85.55 0.07
(0.08%)
EUR-INR
98.89 0.98
(1.00%)
GBP-INR
116.24 0.70
(0.61%)
JPY-INR
0.60 0.01
(0.86%)

EQUITY - MARKET SCREENER

Ipca Laboratories Ltd
Industry :  Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code
ISIN Demat
Book Value()
524494
INE571A01038
271.6399623
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
IPCALAB
41.59
34685.17
EPS(TTM)
Face Value()
Div & Yield %
32.87
1
0.29
 

NTPC's North Karanpura project completes trial operations of unit-3
Jun 12,2025

'With this, the total installed capacity of NTPC on standalone and group basis has become 60,266 MW and 81,368 MW respectively,” the public sector enterprise said in a statement.

The North Karanpura Super Thermal Power Project is India's first supercritical thermal power project to utilize air cooled condenser technology. This technology significantly reduces water consumption, requiring only one-third the water footprint of a conventional water cooled condenser (WCC). The project has been built with an investment of Rs 4,609 crore.

NTPC commenced commercial operation of unit-1 of this project on 01 March 2023. The unit-II of the project became operational on 03 March 2024.

NTPC is India's largest energy conglomerate. It has presence in the entire value chain of the power generation business. As of 31 March 2025, the Government of India held 51.10% stake in the company.

The company had reported 23.4% increase in consolidated net profit to Rs 7,611.22 crore on a 4.6% rise in net sales to Rs 49,833.70 crore in Q4 FY25 as compared with Q4 FY24.

The scrip shed 0.09% to currently trade at Rs 337.75 on the BSE.